Insights into the Management of Overactive Bladder: What Difference Can Mirabegron Make?
Journal Title: JOURNAL OF UROLOGICAL SURGERY - Year 2019, Vol 6, Issue 2
Abstract
Oral pharmacotherapy constitutes second-line treatment for overactive bladder (OAB) after lifestyle modifications, bladder retraining, and pelvic floor muscle exercises. Antimuscarinics have an established role in the treatment of OAB. However, antimuscarinics are known to have low persistence rates in clinical practice. Mirabegron is an oral β3-adrenoreceptor agonist which has emerged as an alternative to antimuscarinics for managing OAB. Overall, mirabegron has similar clinical efficacy to antimuscarinics and is superior to placebo. Mirabegron has been generally well tolerated in both interventional and non-interventional studies. Persistence has been shown to be higher with mirabegron than with antimuscarinics in real-world studies. Increased blood pressure is associated with mirabegron and therefore its use is contraindicated in patients with severe uncontrolled hypertension. However, a low rate of treatment cessation due to cardiovascular issues has been noted in clinical trials. Mirabegron’s utility in the elderly patient population has been well supported with promising efficacy and safety outcomes. New data from a prospective placebo-controlled randomized trial in older OAB patients is expected to be published soon. Mirabegron does not interfere with detrusor contractions during the emptying phase of the micturition cycle and hence lacks any significant effect on post-void residual volume. Mirabegron can be combined with antimuscarinics to synergize clinical effectiveness. Overall, mirabegron represents a well-tolerated and effective medical treatment option for OAB. Mirabegron could be used as an alternative to antimuscarinics, especially in patients who do not improve with antimuscarinics and/or experience bothersome side effects for whom anticholinergic load may be a relevant consideration.
Authors and Affiliations
Ömer Acar, Mustafa Levent Erton, Tufan Tarcan
Keywords
Related Articles
- EP ID EP581531
- DOI 10.4274/jus.galenos.2019.2533
- Views 84
- Downloads 0
Current Status of Histologic Grading in Prostate Carcinoma and Renal Cell Carcinoma
.
Nephrogenic Adenoma of the Urinary Tract in Pediatric Patients: A Report of 2 Cases
Nephrogenic adenoma (NA) is a rare, benign proliferation of glands of the urinary tract, usually occurring as a result of chronic inflammation, trauma or other similar chronic injuries to the urothelial mucosa. We aimed...
Can We Predict Mortality in Patients with Fournier’s Gangrene Using Questionnaires? A Pilot Study with Eighty-seven Patients
Objective: To investigate the validity and reliability of the Fournier’s gangrene severity index (FSGI) and Uludag Fournier’s gangrene severity index (UFGSI) scoring systems and their components in outcome prediction for...
Re: Varicocelectomy to “Upgrade” Semen Quality to Allow Couples to Use Less Invasive Forms of Assisted Reproductive Technology
.
Fournier’s Gangrene: Analysis of Risk Factors Affecting Mortality in a Tertiary Urology Referral Center
Objective: We aimed to investigate the risk factors affecting mortality in patients with Fournier’s gangrene (FG). Materials and Methods: Records of 48 male patients, who were admitted to our urology clinic between Novem...